A new immunotherapy combination has earned regulatory approval in the United Arab Emirates for advanced lung cancer patients whose tumors stopped responding to standard checkpoint inhibitor therapy, marking a potential breakthrough for a notoriously difficult-to-treat group. The approval reflects growing evidence that certain immunotherapy approaches may work better when sequenced differently or combined with agents that boost the immune system in new ways.

What Is Nogapendekin Alfa and How Does It Work?

Nogapendekin alfa inbakicept (brand name Anktiva) is an immunotherapy drug that works by activating a specific immune receptor called MHC-I, which helps the body's T cells recognize and attack cancer cells. The drug is now approved in the UAE in combination with checkpoint inhibitors, a class of immunotherapy drugs that remove the "brakes" cancer cells use to hide from the immune system.

The combination addresses a real clinical problem: some patients with advanced non-small cell lung cancer (NSCLC), the most common type of lung cancer, progress despite receiving checkpoint inhibitor therapy. For these patients, standard options are limited, and survival outcomes have historically been poor. This new approval offers an alternative approach for that population.

What Do the Clinical Trial Results Show?

The approval is supported by findings from the QUILT-2.023 trial, which enrolled 79 patients with advanced NSCLC that had progressed on prior checkpoint inhibitor therapy. Patients received nogapendekin alfa plus a checkpoint inhibitor and were followed to measure survival outcomes.

The results showed a median overall survival of 14.6 months in the full group. However, a subset of patients who achieved a specific immune marker on treatment (an absolute lymphocyte count of at least 1,000 cells per microliter) had notably better outcomes, with a median overall survival of 16.2 months, compared with 11.8 months in those who did not reach that threshold. This 4.4-month difference represents a 52% reduction in the risk of death in the responding group, suggesting the drug works best in patients whose immune systems mount a strong response.

The most common side effects were injection site reactions (occurring in 86% of patients), chills (46%), fatigue (32%), and fever (28%). The good news: most of these were mild to moderate, and no severe or fatal side effects were reported.

How Does This Fit Into the Broader Lung Cancer Treatment Landscape?

This approval arrives at a pivotal moment for early-stage lung cancer treatment. Recent clinical trials have fundamentally shifted thinking about when immunotherapy works best in lung cancer. Four major trials testing adjuvant immunotherapy, meaning immunotherapy given after surgery, showed disappointing results with little to no overall survival benefit. However, trials testing neoadjuvant immunotherapy, meaning immunotherapy given before surgery while the tumor is still present, showed substantial survival improvements.

This pattern suggests that the timing and sequencing of immunotherapy matter enormously. Giving immunotherapy before surgery, when the tumor and its antigens are still present, appears to generate a stronger and more durable immune response than giving the same drug afterward.

What Should Patients and Doctors Know About Treatment Options?

For patients with early-stage lung cancer, the emerging evidence points to several key considerations when deciding on treatment strategy:

• Molecular Testing First: Patients should have their tumors tested for specific genetic mutations, including EGFR, ALK, RET, and other driver mutations, because targeted therapies for these mutations often produce larger survival benefits than immunotherapy alone.
• Neoadjuvant Therapy Preferred: For patients with stage II or III disease without a targetable mutation, neoadjuvant immunotherapy combined with chemotherapy before surgery appears superior to adjuvant immunotherapy after surgery, based on recent trial data.
• Adjuvant Targeted Therapy Delivers: For patients with EGFR-mutated tumors, adjuvant osimertinib (a third-generation EGFR inhibitor) reduced the risk of death by roughly 50% over five years, making it one of the most effective adjuvant strategies available.
• Emerging Options for Progression: For patients whose tumors progress on checkpoint inhibitors, combinations like nogapendekin alfa plus checkpoint inhibitors represent a new option, though identifying which patients will respond requires monitoring immune markers during treatment.

The regulatory landscape is expanding rapidly. Nogapendekin alfa plus BCG (Bacillus Calmette-Guérin, a live bacterial vaccine) is already approved in the United States, United Kingdom, European Union, and Saudi Arabia for non-muscle-invasive bladder cancer with carcinoma in situ. The new UAE approval extends the drug's reach to 34 countries globally and marks the fifth regulatory jurisdiction to authorize it.

"This approval in patients with lung cancer who progressed on checkpoint inhibitors supports the evidence that the MHC-I receptor is lost in patients who progressed on checkpoint inhibitors," stated Patrick Soon-Shiong, founder, executive chairman, and global chief medical and scientific officer of ImmunityBio.

Patrick Soon-Shiong, Founder and Executive Chairman, ImmunityBio

In the United States, the FDA accepted a supplemental application for nogapendekin alfa plus BCG for the papillary-only form of non-muscle-invasive bladder cancer in May 2026, with a decision expected by January 6, 2027. However, the NSCLC indication has not yet been approved in the US, though it was granted accelerated approval in Saudi Arabia in January 2026.

What Are the Key Takeaways for Patients Facing a Lung Cancer Diagnosis?

The convergence of these recent approvals and trial results underscores a fundamental shift in how doctors approach lung cancer treatment. Rather than a one-size-fits-all approach, modern lung cancer care increasingly relies on understanding the specific biology of each patient's tumor and matching that biology to the therapy most likely to work. For patients with early-stage disease, this means molecular testing should happen before surgery to guide decisions about neoadjuvant therapy. For patients with advanced disease that has progressed on standard immunotherapy, new combination approaches like nogapendekin alfa plus checkpoint inhibitors offer hope, though identifying which patients will benefit requires careful monitoring of immune markers during treatment.

The bottom line: lung cancer treatment is becoming more personalized, more sequenced, and increasingly effective, but it requires a multidisciplinary team approach and careful attention to each patient's individual tumor characteristics and treatment history.